UK's MHRA renews Early Access to Medicines Scheme Scientific Opinion for Santhera's Raxone® (idebenone) in Duchenne Muscular Dystrophy

Santhera Pharmaceuticals Holding AG / UK's MHRA renews Early Access to Medicines Scheme Scientific Opinion for Santhera's Raxone® (idebenone) in Duchenne Muscular Dystrophy . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this...

London, 22/06/2018 (informazione.it - comunicati stampa - salute e benessere)